Novel assay improves detection of potential therapeutic tumor targets in human biopsies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers at Baylor College of Medicine and collaborating institutions developed a kinase inhibitor pulldown assay that can optimally enrich and quantify the small amounts of kinases present in biopsy samples in combination with mass-spectrometry techniques. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents


Researchers at Baylor College of Medicine and Texas Children’s Cancer Center were awarded more than $7.6 million over four years from NCI to comprehensively study late effects of childhood cancer in a diverse population of childhood cancer survivors, including their medical, neurocognitive, and psychosocial outcomes. In addition, they will evaluate potential educational and sociodemographic barriers to obtaining survivorship care.